Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Polymyxins, discovered in 1947, are basic lipodecapeptides.
• Clinical use was discontinued in the 1960s due to nephrotoxicity and the advent of safer antibiotics.
• Polymyxins have resurged as critical last-resort treatments for multidrug-resistant bacterial infections.

Purpose of the Study:

• To review the current status and future potential of polymyxin antibiotics.
• To highlight the challenges associated with polymyxin use, primarily nephrotoxicity and narrow therapeutic windows.
• To discuss ongoing research and development of novel polymyxin derivatives.

Main Methods:

• This article is a perspective piece, synthesizing existing literature and research trends.
• It analyzes the historical context, current clinical challenges, and future directions in polymyxin development.
• Focuses on the design and potential advantages of new polymyxin derivatives.

Main Results:

• Despite toxicity, polymyxins remain vital for treating infections caused by extremely multidrug-resistant strains.
• Current polymyxin use is limited by nephrotoxicity, necessitating lower doses and leading to suboptimal efficacy.
• Significant investment is being made in developing novel polymyxin derivatives with improved therapeutic profiles.

Conclusions:

• Polymyxins possess considerable potential for further development.
• Novel polymyxin derivatives currently in development may offer significant advantages over existing formulations.
• Addressing nephrotoxicity and enhancing efficacy are key goals for future polymyxin therapies.